Aclarion Expands CLUE Trial to New Jersey
Aclarion, Inc. is excited to announce that it is expanding its multi-center Clinical Utility and Economic (CLUE) Trial to New Jersey. This groundbreaking trial is designed to evaluate how effectively Nociscan's AI technology can change initial treatment strategies for patients suffering from chronic low back pain.
Introducing Dr. Justin Kubeck
Dr. Justin Kubeck, an orthopedic spine surgeon and founder of Ocean Pain and Spine, will lead this important initiative. His expertise is a significant addition to the expanding network of spine surgeons involved in the CLUE Trial. This collaboration is crucial for gathering strong data that highlights the value of incorporating Nociscan's AI-generated insights into traditional diagnostic methods for chronic low back pain.
Second Surgeon Joins the CLUE Trial
With Dr. Kubeck's involvement, the CLUE Trial welcomes its second participating surgeon, advancing the trial's goal of providing comprehensive data on how often Nociscan affects treatment decisions. This development follows the recent addition of Dr. John Keller from Michigan, showcasing the trial's swift growth and the rising interest among spine specialists.
The Role of Nociscan in Treatment Decisions
Dr. Kubeck discusses the importance of customized treatment plans for his patients. He stresses that each case requires a unique approach, where options such as medication, therapy, or surgery are thoughtfully evaluated. He believes that Nociscan will be a vital decision-support tool, enhancing the diagnostic process and improving treatment planning.
Global Impact of Chronic Low Back Pain
Chronic low back pain and degenerative spine diseases affect approximately 266 million people worldwide. Recognizing the challenges faced by this population, Aclarion’s Nociscan solution aims to make a significant impact. It is the first SaaS platform that offers evidence-based support to help physicians effectively differentiate between painful and nonpainful discs in the lumbar spine.
Understanding Nociscan's Technology
Nociscan utilizes advanced technology to measure chemical biomarkers linked to disc pain. The clinical data collected from patients is analyzed using proprietary algorithms to determine whether a specific disc may be causing discomfort. This efficient, non-invasive process not only improves diagnostic accuracy but also empowers physicians to make well-informed decisions regarding the most appropriate treatment strategies.
Value of Real-World Evidence in Healthcare
The importance of real-world evidence in medicine cannot be overstated. Ryan Bond, Chief Strategy Officer at Aclarion, emphasizes that the insights gathered from practicing surgeons through clinical trials like CLUE are invaluable. Such data not only demonstrates the utility and effectiveness of diagnostic tools like Nociscan but also plays a significant role in shaping insurance coverage decisions.
Invitation for Participation
Aclarion's expanding CLUE Trial is generating considerable interest, and the company is eager to welcome more healthcare providers to participate. Those interested are encouraged to reach out to Aclarion via email to learn how they can bring the benefits of Nociscan to their patients and join this transformative clinical trial.
About Aclarion, Inc.
Aclarion, Inc. is a pioneering healthcare technology company focused on leveraging Magnetic Resonance Spectroscopy (MRS), proprietary algorithms, and augmented intelligence to enhance clinical outcomes. Aimed at addressing chronic low back pain, Aclarion offers Nociscan, a leading evidence-based SaaS solution designed to assist physicians in accurately diagnosing lumbar disc pain.
Nociscan's Operational Mechanism
Through an innovative cloud-based network, Nociscan gathers MRS data from MRI machines. This data is processed using advanced signal processing techniques to extract and quantify relevant biomarkers. The structured data then feeds into algorithms to identify potential sources of pain, enabling clinicians to optimize treatment plans for their patients.
Frequently Asked Questions
What is the purpose of the CLUE Trial?
The CLUE Trial aims to evaluate how much Nociscan's AI data influences the treatment plans for patients suffering from chronic low back pain.
Who is participating in the CLUE Trial?
Currently, Dr. Justin Kubeck and Dr. John Keller are participating, with more spine surgeons expected to join soon.
How does Nociscan work?
Nociscan uses biomarkers from MRS data to help distinguish between painful and nonpainful spinal discs, providing crucial diagnostic insights.
What is the significance of real-world evidence in healthcare?
Real-world evidence offers valuable insights into the effectiveness of diagnostic tools like Nociscan, influencing healthcare decisions and payer coverage.
How can providers participate in the CLUE Trial?
Healthcare providers interested in participating can reach out to Aclarion for more information about bringing Nociscan to their practice.
